Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(23)00020-7 | DOI Listing |
Publication Analysis
Top Keywords
modernising fda's
4
fda's accelerated
4
accelerated approval
4
approval pathway
4
modernising
1
accelerated
1
approval
1
pathway
1
Similar Publications
Modernising the US FDA's Accelerated Approval pathway.
Lancet Oncol
March 2023
Department of Surgery and Cancer, Imperial College, London, UK; Hammersmith Hospital, London, UK.
Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes. Iodine-131 tositumomab has a dual mechanism of action. It is capable of initiating a host immune response to those B cells to which it is attached, and it also triggers apoptosis in a significant proportion of the cells to which it binds.
View Article and Find Full Text PDF